Capital Fund Management (CFM)
MRNA icon

Capital Fund Management (CFM)’s Moderna MRNA Stock Holding History

Capital Fund Management (CFM)’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.1M Sell
257,000
-289,600
-53% -$13.5M 0.06% 453
2025
Q4 		$16.1M Sell
546,600
-244,900
-31% -$6.65M 0.04% 584
2025
Q3 		$20.4M Sell
791,500
-915,100
-54% -$25.5M 0.05% 508
2025
Q2 		$47.1M Sell
1,706,600
-998,200
-37% -$26.3M 0.13% 220
2025
Q1 		$76.7M Buy
2,704,800
+928,600
+52% +$33M 0.22% 118
2024
Q4 		$73.9M Buy
1,776,200
+1,385,200
+354% +$66.2M 0.19% 147
2024
Q3 		$26.1M Sell
391,000
-102,400
-21% -$9.4M 0.07% 367
2024
Q2 		$58.6M Sell
493,400
-221,500
-31% -$28M 0.17% 169
2024
Q1 		$76.2M Sell
714,900
-604,300
-46% -$60.9M 0.22% 111
2023
Q4 		$131M Buy
1,319,200
+575,200
+77% +$48.4M 0.35% 41
2023
Q3 		$76.8M Buy
744,000
+420,500
+130% +$46.9M 0.27% 86
2023
Q2 		$39.3M Buy
323,500
+215,400
+199% +$28.7M 0.16% 165
2023
Q1 		$16.6M Sell
108,100
-165,100
-60% -$27.2M 0.08% 341
2022
Q4 		$49.1M Sell
273,200
-175,100
-39% -$28.6M 0.33% 58
2022
Q3 		$53M Buy
448,300
+42,700
+11% +$6.48M 0.42% 44
2022
Q2 		$57.9M Sell
405,600
-32,400
-7% -$4.63M 0.53% 19
2022
Q1 		$75.4M Sell
438,000
-64,300
-13% -$10.8M 0.62% 9
2021
Q4 		$128M Sell
502,300
-18,900
-4% -$5.53M 0.92% 2
2021
Q3 		$201M Buy
521,200
+21,500
+4% +$7.93M 1.49% 1
2021
Q2 		$117M Buy
499,700
+230,100
+85% +$41.1M 0.93% 4
2021
Q1 		$35.3M Buy
+269,600
New +$39.1M 0.39% 51

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Fund Management (CFM)'s MRNA Position: Q1 2026 in Review

Capital Fund Management (CFM) reduced its Moderna (MRNA) stake by 39% in Q1 2026, selling an estimated $17.1M and leaving 569,930 shares worth $29M. The position accounts for 0.13% of the portfolio, ranked #196.

Capital Fund Management (CFM) first reported a position in MRNA in Q2 2020 and has held it in 15 quarters since. The position peaked at $57M in Q4 2024. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Capital Fund Management (CFM) held 569,930 shares of Moderna worth $29M as of Q1 2026.
  • Capital Fund Management (CFM) sold 367,150 Moderna shares in Q1 2026, an estimated $17.1M.
  • Moderna made up 0.13% of Capital Fund Management (CFM)'s portfolio in Q1 2026, its #196 holding.
  • Capital Fund Management (CFM) first reported a position in Moderna in Q2 2020 and has held it in 15 quarters since.
  • Capital Fund Management (CFM)'s Moderna position peaked at $57M in Q4 2024.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.